RE: Orphan Status26 Jun 2024 06:31
Just for clarity, this is from the post that kindly transcribed and relayed what was said in the Telegram group. Thanks again to the poster that put it there. I think it's really important.
"5. Dan mentioned 3 aspects they are dealing with, these are his own words:
• Most big pharma, not all, don’t like reprofiling (re-using known drugs). It wouldn’t surprise you if I said we’re speaking with AZ, you don’t have to be a genius to join the dots. They currently love IPF. We know them well. But they don’t like reprofiling. So the IP piece becomed more important, and the deal is just harder overall. We also don’t have orphan status. Every other asset out there has got orphan status already. To compete, I think personally we need that. Ideally from the European vs the US. If we go for European orphan designation, we have to present our existing data and rationale. If it’s accepted, it acts like a badge of honour – independent validation we’ve got potential – so drug companies like it. Plus they get a lot of downstream benefits. Shorter development pathways, R&D spend rebates, etc. So we really need to get that in place I think to close something. It will take up to 3 months to get orphan status. We want to start immediately."
I'm not going bang on about this anymore. I just want people to remember what was said just before we got hit with the last fundraiser. We want to see progress being made and words being kept.